THECardiac Wire
Thu, Oct 15, 2026 · Vol. 1, No. 1ArchiveAboutSubscribe
Clinical Trials UpdateThursday, October 15, 2026

AtriCure (ATRC) Leans On Trial Progress As Fair Value Sits Just Below The Stock - Simply Wall Street

1 min read·By E. Nolan Beckett, MD·Source: Simply Wall Street
From The Cardiac Wire

Coronary [LANDMARK] NCT07871591 : TOP-CABG Trial Follow-up Extension (TOP-CABG FE).

Not yet recruiting, N/A phase, enrollment 2,290, sponsor China National Center for Cardiovascular Diseases.

Editor’s take pending for this article; this is the section commentary excerpt.
Source Abstract

AtriCure (ATRC) Leans On Trial Progress As Fair Value Sits Just Below The Stock Simply Wall Street

Read the Original
Full article at Simply Wall Street
Open at Simply Wall Street →
The Cardiac Wire summarizes; we link out to primary sources for verification.
More in Clinical Trials Update
Elsewhere in Today’s Issue